What’s Next for Cell and Gene Therapy?

<div class="ag87-crtemvc-hsbk"><div class="css-vsf5of"><p class="carina-rte-public-DraftStyleDefault-block"><span style="color: rgb(29,28,29);">Cell and gene therapies are powerful technologies that can address the root causes of disease. But, today, only liquid cancers and a very small number of genetic illnesses can be addressed. These therapies are also far too expensive and difficult to manufacture. As a result, these therapies are used as last-resort options rather than first-line treatments. What will it take to make cell and gene therapies more precise and more cost-effective? Is it better to take an allogeneic or autologous approach? How will the regulatory landscape need to adapt for these therapies and can we expect to see in the next 3-5 years?</span></p></div></div>